Cancer diagnostics News and Research

RSS

Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) today announced that it has entered into agreements with a syndicate of institutional investors for up to $2.0 million. LifeTech Capital, a division of Aurora Capital LLC, acted as the exclusive placement agent for the financing.

17 Mar 2010

Colon cancer patients often not treated with recommended level of chemotherapy

New results from a major initiative on the quality of cancer care in the United States show that patients with a common type of colon cancer -- especially older patients -- often are not treated as aggressively with chemotherapy as research shows is necessary to improve survival.

17 Mar 2010

Celerus Diagnostics to present Wave RPD totally automated HC staining system at annual USCAP meeting

Celerus Diagnostics will introduce a totally automated immunohistochemistry (IHC) staining system, the much-anticipated Wave RPD, at the United States and Canadian Association of Pathologists (USCAP) annual meeting being held in Washington DC, March 22–24. The new system is the first of its kind, capable of delivering totally automated IHC results in one hour.

17 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Biomoda, Obio collaborate to expand Biomoda’s lung cancer screening program for veterans into Ohio

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) and Obio, Inc., a corporation formed to pursue public and private funding for cancer research in Ohio, are working together to expand Biomoda’s lung cancer screening program for veterans into Ohio.

10 Mar 2010

Team Lung Love: New endurance sports training program focused on raising awareness for lung cancer

Lung Cancer Alliance announced the launch of Team Lung Love (TLL), an endurance sports training program focused exclusively on raising awareness and support for lung cancer.

10 Mar 2010

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

OVA1™, the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer, is now available nationally through Quest Diagnostics, Inc., the world's leading cancer diagnostics provider.

From Quest Diagnostics 10 Mar 2010

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

New research published in today's issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive.

9 Mar 2010

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.

8 Mar 2010

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

Breast cancer patients with early stage disease that has spread to only one lymph node may not benefit from radiation after mastectomy, because of the low present-day risk of recurrence following modern surgery and systemic therapy, a finding that could one day change the course of treatment for thousands of women diagnosed each year, according to researchers at The University of Texas M. D. Anderson Cancer.

7 Mar 2010

New guidance produced to help GPs identify symptoms of cervical cancer in young women

New guidance has been produced to help GPs identify symptoms of cervical cancer and facilitate early diagnosis of the disease in young women.

6 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

Research explores the importance of patient's outlook on health behavior and health status

Research published in the March edition of the Journal of Thoracic Oncology explored the importance of a patient's outlook as it relates to health behavior and health status. Researchers focused on lung cancer patients and discovered that those who exhibited an optimistic disposition experienced more favorable outcomes than those with a pessimistic disposition.

4 Mar 2010

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

An imaging technique combining ultrasound and specially modified contrast agents may allow researchers to noninvasively detect cancer and show its progression, according to research published in the March issue of The Journal of Nuclear Medicine (JNM). The technique enables researchers to visualize tumor activity at the molecular level.

2 Mar 2010

GenWay Biotech's simple blood sample cancer assessment test

San Diego-based GenWay Biotech, Inc. today announced the availability of the You Test You- Cancer Assessment that allows patients to test for various types of cancer without having to visit their doctor's office, through a simple blood sample. With a 10-day turnaround time and a cost of $149, You Test You- is a convenient and low cost way to periodically test for indication of cancer.

2 Mar 2010

Study evaluates possible diet associations with ovarian cancer survival

2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.

1 Mar 2010

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

A recent Avon Foundation for Women survey confirms what the American College of Radiology and other experts warned would happen: states are using deeply flawed and widely discredited U.S. Preventative Services Task Force mammography recommendations to deny women coverage for mammograms, and many women are foregoing long proven, life-saving mammography care based on the mistaken USPSTF recommendations.

23 Feb 2010

WCMC-Q students receive new round of UREP funds totaling $280,000

Twenty-eight WCMC-Q students have received grants totaling $280,000 in the latest, seventh, round of funding from the Undergraduate Research Experience Program (UREP) to conduct advanced research projects with faculty members.

22 Feb 2010

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Genoptix, Inc., a specialized laboratory service provider, and HistoRx, Inc. (privately held), a diagnostics company, today announced a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it.

19 Feb 2010

Cancer diagnostics News and Research

Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M

Colon cancer patients often not treated with recommended level of chemotherapy

Celerus Diagnostics to present Wave RPD totally automated HC staining system at annual USCAP meeting

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Biomoda, Obio collaborate to expand Biomoda’s lung cancer screening program for veterans into Ohio

Team Lung Love: New endurance sports training program focused on raising awareness for lung cancer

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

New guidance produced to help GPs identify symptoms of cervical cancer in young women

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Research explores the importance of patient's outlook on health behavior and health status

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

GenWay Biotech's simple blood sample cancer assessment test

Study evaluates possible diet associations with ovarian cancer survival

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

WCMC-Q students receive new round of UREP funds totaling $280,000

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News